Intravenous Nicardipine for Treatment of Postcoarctectomy Hypertension in Children

Thomas Nakagawa, S. C. Sartori, A. Morris, D. S. Schneider

Research output: Contribution to journalArticle

Abstract

Our objective was to evaluate the efficacy of intravenous (IV) nicardipine for the treatment of postcoarctectomy hypertension in children with coarctation of the aorta. We carried out a retrospective review in a pediatric intensive care unit at a tertiary care children's hospital. The patients were children with coarctation of the aorta treated for postcoarctectomy hypertension. Children with postcoarctectomy hypertension defined as a systolic blood pressure >95th percentile for age measured by indwelling arterial catheter were treated with IV nicardipine. We measured change in mean arterial blood pressure (MAP), mean systolic and diastolic blood pressure, and mean heart rate (HR) from baseline after initiating treatment with IV nicardipine. The outcome measure was a reduction in MAP and mean systolic and diastolic blood pressure after treatment with IV nicardipine. During a 4-year period, 10 children met the study criteria. Median age was 3.25 months (range, 0.25 to 180 months). Initial median treatment dose of IV nicardipine was 1.0 μg/kg/min (range, 0. 5 to 6 μg/kg/min); median dose used to control hypertension was 1.5 μg/kg/min (range, 0.25 to 6 μg/kg/ min). Median duration of therapy was 26.3 h (range, 13 to 49 h). Treatment with IV nicardipine resulted in a 26.5% decrease in MAP from baseline during the first hour of treatment (p = 0.0006). Mean systolic blood pressure decreased from 133 to 105 mmHg (p = 0.005), and mean diastolic blood pressure decreased from 75 to 52.5 mmHg (p = 0.001) during the first hour of therapy with nicardipine. There was a significant reduction (p = 0.0005) in MAP during continued treatment with IV nicardipine. The mean HR of 150 remained unchanged during the first hour of therapy with nicardipine, and no significant change in mean HR or adverse effects was noted during continued therapy. Two children receiving other antihypertensive therapy demonstrated further reduction in their blood pressure when IV nicardipine was initiated. Tachycardia and hypotension were not observed in any child treated with IV nicardipine. We concluded that IV nicardipine reduced MAP with no significant change in mean HR and no adverse effects in patients with postcoarctectomy hypertension. Nicardipine produced a further reduction in MAP in children receiving other antihypertensive agents. Nicardipine is an effective agent for treatment of post-coarctectomy hypertension in children with coarctation of the aorta.

Original languageEnglish (US)
Pages (from-to)26-30
Number of pages5
JournalPediatric Cardiology
Volume25
Issue number1
DOIs
StatePublished - Jan 2004
Externally publishedYes

Fingerprint

Nicardipine
Arterial Pressure
Hypertension
Blood Pressure
Therapeutics
Aortic Coarctation
Heart Rate
Antihypertensive Agents
Pediatric Intensive Care Units
Indwelling Catheters
Tertiary Healthcare
Tachycardia
Hypotension

Keywords

  • Coarctation of the aorta
  • Hypertension
  • Nicardipine

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pediatrics, Perinatology, and Child Health

Cite this

Intravenous Nicardipine for Treatment of Postcoarctectomy Hypertension in Children. / Nakagawa, Thomas; Sartori, S. C.; Morris, A.; Schneider, D. S.

In: Pediatric Cardiology, Vol. 25, No. 1, 01.2004, p. 26-30.

Research output: Contribution to journalArticle

Nakagawa, Thomas ; Sartori, S. C. ; Morris, A. ; Schneider, D. S. / Intravenous Nicardipine for Treatment of Postcoarctectomy Hypertension in Children. In: Pediatric Cardiology. 2004 ; Vol. 25, No. 1. pp. 26-30.
@article{01fb9bdce34042ba937921bbf3b0ac84,
title = "Intravenous Nicardipine for Treatment of Postcoarctectomy Hypertension in Children",
abstract = "Our objective was to evaluate the efficacy of intravenous (IV) nicardipine for the treatment of postcoarctectomy hypertension in children with coarctation of the aorta. We carried out a retrospective review in a pediatric intensive care unit at a tertiary care children's hospital. The patients were children with coarctation of the aorta treated for postcoarctectomy hypertension. Children with postcoarctectomy hypertension defined as a systolic blood pressure >95th percentile for age measured by indwelling arterial catheter were treated with IV nicardipine. We measured change in mean arterial blood pressure (MAP), mean systolic and diastolic blood pressure, and mean heart rate (HR) from baseline after initiating treatment with IV nicardipine. The outcome measure was a reduction in MAP and mean systolic and diastolic blood pressure after treatment with IV nicardipine. During a 4-year period, 10 children met the study criteria. Median age was 3.25 months (range, 0.25 to 180 months). Initial median treatment dose of IV nicardipine was 1.0 μg/kg/min (range, 0. 5 to 6 μg/kg/min); median dose used to control hypertension was 1.5 μg/kg/min (range, 0.25 to 6 μg/kg/ min). Median duration of therapy was 26.3 h (range, 13 to 49 h). Treatment with IV nicardipine resulted in a 26.5{\%} decrease in MAP from baseline during the first hour of treatment (p = 0.0006). Mean systolic blood pressure decreased from 133 to 105 mmHg (p = 0.005), and mean diastolic blood pressure decreased from 75 to 52.5 mmHg (p = 0.001) during the first hour of therapy with nicardipine. There was a significant reduction (p = 0.0005) in MAP during continued treatment with IV nicardipine. The mean HR of 150 remained unchanged during the first hour of therapy with nicardipine, and no significant change in mean HR or adverse effects was noted during continued therapy. Two children receiving other antihypertensive therapy demonstrated further reduction in their blood pressure when IV nicardipine was initiated. Tachycardia and hypotension were not observed in any child treated with IV nicardipine. We concluded that IV nicardipine reduced MAP with no significant change in mean HR and no adverse effects in patients with postcoarctectomy hypertension. Nicardipine produced a further reduction in MAP in children receiving other antihypertensive agents. Nicardipine is an effective agent for treatment of post-coarctectomy hypertension in children with coarctation of the aorta.",
keywords = "Coarctation of the aorta, Hypertension, Nicardipine",
author = "Thomas Nakagawa and Sartori, {S. C.} and A. Morris and Schneider, {D. S.}",
year = "2004",
month = "1",
doi = "10.1007/s00246-003-0497-0",
language = "English (US)",
volume = "25",
pages = "26--30",
journal = "Pediatric Cardiology",
issn = "0172-0643",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Intravenous Nicardipine for Treatment of Postcoarctectomy Hypertension in Children

AU - Nakagawa, Thomas

AU - Sartori, S. C.

AU - Morris, A.

AU - Schneider, D. S.

PY - 2004/1

Y1 - 2004/1

N2 - Our objective was to evaluate the efficacy of intravenous (IV) nicardipine for the treatment of postcoarctectomy hypertension in children with coarctation of the aorta. We carried out a retrospective review in a pediatric intensive care unit at a tertiary care children's hospital. The patients were children with coarctation of the aorta treated for postcoarctectomy hypertension. Children with postcoarctectomy hypertension defined as a systolic blood pressure >95th percentile for age measured by indwelling arterial catheter were treated with IV nicardipine. We measured change in mean arterial blood pressure (MAP), mean systolic and diastolic blood pressure, and mean heart rate (HR) from baseline after initiating treatment with IV nicardipine. The outcome measure was a reduction in MAP and mean systolic and diastolic blood pressure after treatment with IV nicardipine. During a 4-year period, 10 children met the study criteria. Median age was 3.25 months (range, 0.25 to 180 months). Initial median treatment dose of IV nicardipine was 1.0 μg/kg/min (range, 0. 5 to 6 μg/kg/min); median dose used to control hypertension was 1.5 μg/kg/min (range, 0.25 to 6 μg/kg/ min). Median duration of therapy was 26.3 h (range, 13 to 49 h). Treatment with IV nicardipine resulted in a 26.5% decrease in MAP from baseline during the first hour of treatment (p = 0.0006). Mean systolic blood pressure decreased from 133 to 105 mmHg (p = 0.005), and mean diastolic blood pressure decreased from 75 to 52.5 mmHg (p = 0.001) during the first hour of therapy with nicardipine. There was a significant reduction (p = 0.0005) in MAP during continued treatment with IV nicardipine. The mean HR of 150 remained unchanged during the first hour of therapy with nicardipine, and no significant change in mean HR or adverse effects was noted during continued therapy. Two children receiving other antihypertensive therapy demonstrated further reduction in their blood pressure when IV nicardipine was initiated. Tachycardia and hypotension were not observed in any child treated with IV nicardipine. We concluded that IV nicardipine reduced MAP with no significant change in mean HR and no adverse effects in patients with postcoarctectomy hypertension. Nicardipine produced a further reduction in MAP in children receiving other antihypertensive agents. Nicardipine is an effective agent for treatment of post-coarctectomy hypertension in children with coarctation of the aorta.

AB - Our objective was to evaluate the efficacy of intravenous (IV) nicardipine for the treatment of postcoarctectomy hypertension in children with coarctation of the aorta. We carried out a retrospective review in a pediatric intensive care unit at a tertiary care children's hospital. The patients were children with coarctation of the aorta treated for postcoarctectomy hypertension. Children with postcoarctectomy hypertension defined as a systolic blood pressure >95th percentile for age measured by indwelling arterial catheter were treated with IV nicardipine. We measured change in mean arterial blood pressure (MAP), mean systolic and diastolic blood pressure, and mean heart rate (HR) from baseline after initiating treatment with IV nicardipine. The outcome measure was a reduction in MAP and mean systolic and diastolic blood pressure after treatment with IV nicardipine. During a 4-year period, 10 children met the study criteria. Median age was 3.25 months (range, 0.25 to 180 months). Initial median treatment dose of IV nicardipine was 1.0 μg/kg/min (range, 0. 5 to 6 μg/kg/min); median dose used to control hypertension was 1.5 μg/kg/min (range, 0.25 to 6 μg/kg/ min). Median duration of therapy was 26.3 h (range, 13 to 49 h). Treatment with IV nicardipine resulted in a 26.5% decrease in MAP from baseline during the first hour of treatment (p = 0.0006). Mean systolic blood pressure decreased from 133 to 105 mmHg (p = 0.005), and mean diastolic blood pressure decreased from 75 to 52.5 mmHg (p = 0.001) during the first hour of therapy with nicardipine. There was a significant reduction (p = 0.0005) in MAP during continued treatment with IV nicardipine. The mean HR of 150 remained unchanged during the first hour of therapy with nicardipine, and no significant change in mean HR or adverse effects was noted during continued therapy. Two children receiving other antihypertensive therapy demonstrated further reduction in their blood pressure when IV nicardipine was initiated. Tachycardia and hypotension were not observed in any child treated with IV nicardipine. We concluded that IV nicardipine reduced MAP with no significant change in mean HR and no adverse effects in patients with postcoarctectomy hypertension. Nicardipine produced a further reduction in MAP in children receiving other antihypertensive agents. Nicardipine is an effective agent for treatment of post-coarctectomy hypertension in children with coarctation of the aorta.

KW - Coarctation of the aorta

KW - Hypertension

KW - Nicardipine

UR - http://www.scopus.com/inward/record.url?scp=0942297986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0942297986&partnerID=8YFLogxK

U2 - 10.1007/s00246-003-0497-0

DO - 10.1007/s00246-003-0497-0

M3 - Article

C2 - 14534761

AN - SCOPUS:0942297986

VL - 25

SP - 26

EP - 30

JO - Pediatric Cardiology

JF - Pediatric Cardiology

SN - 0172-0643

IS - 1

ER -